Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a large decline in short interest in September. As of September 15th, there was short interest totalling 14,800 shares, a decline of 52.3% from the August 31st total of 31,000 shares. Based on an average daily volume of 144,500 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Xilio Therapeutics stock. XTX Topco Ltd purchased a new position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 33,289 shares of the company’s stock, valued at approximately $32,000. XTX Topco Ltd owned approximately 0.08% of Xilio Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Trading Up 2.6 %

Shares of NASDAQ XLO opened at $0.75 on Thursday. The company has a fifty day moving average price of $0.86 and a 200 day moving average price of $0.97. The firm has a market cap of $27.76 million, a PE ratio of -0.29 and a beta of -0.10. Xilio Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.89.

Xilio Therapeutics (NASDAQ:XLO) last released its earnings results on Thursday, August 8th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The business had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $30.00 million. Equities research analysts forecast that Xilio Therapeutics will post -1.26 EPS for the current year.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.